← All trials
NCT04177355
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2019
- Primary completion
- Mar 18, 2022
- Completion date
- Mar 18, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 105
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of WashingtonCollaborator
- Emory UniversityStudy chair
- University of WashingtonStudy chair
- Dynavax Technologies CorporationCollaborator
- HIV Vaccine Trials NetworkCollaborator
- International AIDS Vaccine InitiativeCollaborator
- Infectious Disease Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.